Navigating the landscape for this new medication and the GLP-1 receptor agonist in the UK can be difficult. Currently, procurement through the NHS is uncommon, meaning many patients are exploring non-NHS pathways to get these promising medications. Purchasing these drugs requires careful thought of legitimate providers and understanding the regulat